Description
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting analogue of Growth Hormone–Releasing Hormone (GHRH). The DAC modification allows the peptide to bind circulating albumin, significantly extending its half-life compared with short-acting GHRH fragments such as Sermorelin or Modified GRF (1–29).
In controlled research settings, CJC-1295 DAC is used to model sustained GH and IGF-1 elevation, long-term somatotropic axis stimulation, body-composition and visceral adiposity changes, and broader metabolic and protein-turnover pathways. Because of its prolonged activity, CJC-1295 DAC is typically explored with weekly or bi-weekly exposure models rather than daily administration.
Mechanism of Action
CJC-1295 DAC functions as a GHRH receptor agonist. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating endogenous, pulsatile growth hormone (GH) release. The DAC side chain enables a stable association with albumin, which protects the peptide from rapid enzymatic breakdown, extending its activity over several days.
This sustained GH stimulation leads to increased IGF-1 levels and influences downstream processes including protein synthesis, lipolysis and tissue-signalling pathways. Research models have explored CJC-1295 DAC in the context of growth, body composition, visceral adiposity and metabolic regulation.
Dosage Protocol — Pen System
The Clinic standardises all cartridges to simplify research use and dose reproducibility.
- Pen volume: 2 mL
- Total clicks per pen: 200 clicks
- CJC-1295 DAC content per cartridge: 5 mg (5,000 mcg)
- Strength: 5 mg ÷ 200 clicks = 0.025 mg (25 mcg) per click
- Reference points: 10 clicks = 250 mcg, 20 clicks = 500 mcg, 40 clicks = 1,000 mcg, 60 clicks = 1,500 mcg
This configuration comfortably satisfies The Clinic requirement that mid-range doses utilise at least 10 clicks.
Suggested Dosing (Pen Format – Example Once-Weekly Protocol)
| Research Arm / Phase |
Reference Dose (mcg) |
Clicks per Injection |
Example Use-Case (Research Context) |
| Low-Exposure Arm (Weeks 1–4) |
500 mcg |
20 clicks |
Initial GH/IGF-1 response, safety and assay calibration |
| Standard Arm (Weeks 5–8) |
1,000 mcg (1.0 mg) |
40 clicks |
Sustained GH/IGF-1 elevation, body-composition signalling |
| High-Exposure Arm (Weeks 9–12) |
1,500 mcg (1.5 mg) |
60 clicks |
Higher-dose endocrine and metabolic outcome exploration |
All values are illustrative research frameworks only and must be aligned with the specific model, ethics approvals and study design. They are not prescribing guidance or human dosing recommendations.
Frequency & Cycle Length
- Frequency: Typically once-weekly subcutaneous injections in long-acting GHRH models.
- Alternative designs: Some protocols explore bi-weekly intervals to map decay curves and hormone profiles.
- Cycle length: GH-axis studies commonly run 8–12 weeks; extended metabolic or body-composition models may run 12–24 weeks.
Product Details & Cartridge Summary
Product Information
- Compound: CJC-1295 with DAC (long-acting GHRH analogue)
- Content: 5 mg CJC-1295 DAC per 2 mL cartridge
What’s in the Box
- 1 × CJC-1295 DAC 5 mg pre-reconstituted in 2 mL bacteriostatic water (Clinic pen compatible)
- 1 × replacement needle
Expected Outcomes
In controlled settings, CJC-1295 DAC exposure has been associated with:
- Persistent elevation of GH and IGF-1 after single or repeated weekly doses.
- Potential improvements or maintenance of lean tissue indices in selected models.
- Exploratory data on visceral adiposity and metabolic parameters in obesity and lipodystrophy frameworks.
These observations are derived from research and must not be interpreted as therapeutic or guaranteed outcomes.
Disclaimer: Supplied strictly for laboratory, educational and research use only. Not for medical, performance or therapeutic use. This product is not registered as a medicine or dietary supplement. All handling, storage and disposal must comply with applicable laws and institutional standards.
Key Themes
- Enhanced pulsatile GH signalling in short-acting GHRH models.
- IGF-1 elevation aligned with physiologic endocrine patterns.
- Sleep and circadian GH-response investigations.
- Synergistic GH amplification when combined with ghrelin agonists such as Ipamorelin.
- Body-composition, recovery and metabolic-pathway research frameworks.
Dosage Protocol — Pen System
The Clinic standardises all cartridges to simplify research use and dose reproducibility.
- Pen volume: 2 mL
- Total clicks per pen: 200 clicks
- CJC-1295 No DAC content per cartridge: 2 mg (2,000 mcg)
- Strength: 2 mg ÷ 200 clicks = 0.01 mg (10 mcg) per click
- Reference points: 10 clicks = 100 mcg, 20 clicks = 200 mcg, 30 clicks = 300 mcg, 40 clicks = 400 mcg
This configuration meets The Clinic requirement of a minimum mid-point dose of at least 10 clicks.
Suggested Research Dosing – Daily Pulsatile Model
| Phase |
Reference Dose (mcg) |
Clicks per Event |
Notes |
| Baseline (Weeks 1–2) |
100–150 mcg |
10–15 clicks |
GH-axis mapping and IGF-1 baseline response |
| Standard Phase (Weeks 3–6) |
200 mcg |
20 clicks |
Core pulsatile GH modelling |
| High-Pulse Arm (Weeks 7–10) |
300 mcg |
30 clicks |
Increased GH peak amplitude comparison |
Synergy Model – Combined with GHS (e.g. Ipamorelin)
| Timing |
Reference Dose (mcg) |
Clicks per Event |
Notes |
| Pre-Sleep |
200–300 mcg |
20–30 clicks |
Aligns with endogenous nocturnal GH spike |
| Optional AM Pulse |
100–200 mcg |
10–20 clicks |
Used in dual-pulse endocrine mapping with GHS overlays |
All dosing values above are illustrative examples only and must be tailored to the specific model, approvals and study design. They are not prescribing guidance.
Frequency & Cycle Length
- Frequency: Typically 1–2 events per day, often around sleep or fasting windows.
- Cycle length: GH-axis and sleep studies often run 4–8 weeks; body-composition/metabolic models 8–12 weeks.
Expected Outcomes
In laboratory and model systems, CJC-1295 No DAC exposure has been associated with:
- Increased pulsatile GH amplitude and frequency.
- IGF-1 elevations consistent with physiologic endocrine patterns.
- Improved slow-wave sleep endocrine alignment in sleep-focused models.
- Exploratory data on lean mass signalling and fat-oxidation pathways.
- Enhanced GH response in combination protocols with ghrelin agonists such as Ipamorelin.
These findings are research observations only and must not be interpreted as guaranteed or therapeutic outcomes.